Gupta Viney, Srinivasan Geetha, Sharma Ajay, Kapoor Kulwant S, Sihota Ramanjit
Department of Ophthalmology, Glaucoma Research Facility & Clinical Services, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
J Ocul Pharmacol Ther. 2007 Aug;23(4):351-8. doi: 10.1089/jop.2006.0107.
The aim of this study was to compare the long-term efficacy of bimatoprost 0.03% monotherapy in primary open angle glaucoma (POAG) versus primary chronic angle closure glaucoma (PCACG) eyes.
A total of 55 consecutive primary adult glaucoma patients on bimatoprost monotherapy were prospectively evaluated in this 3-year, open-labeled, uncontrolled study. The primary outcome was the evaluation of a difference in the response to therapy of POAG eyes, as compared to PCACG eyes over a follow-up of 3 years.
In the POAG group, the mean intraocular pressure (IOP) at the 36-month followup was found to be increased by 2.10 (+/-3.90) mmHg (confidence interval [CI], 0.975-4.185), compared to the mean IOP at 1 month (P = 0.047). In the PCACG group, the mean IOP at the 36-month follow-up was increased by 3.66) (+/- 3.34) mmHg (CI, 6.241-1.092), compared to the mean IOP at 1 month (P = 0.011). This upward drift in IOP was higher in the PCACG group, compared to the POAG group, but this was not statistically significant (P = 0.54). Patients with POAG and PCACG showed a 50% and 40% chance of having an IOP of <18 mmHg with bimatoprost monotherapy (P = 0.23), respectively, at the 3-year follow-up.
This study showed that bimatoprost 0.03% monotherapy significantly lowers IOP in both POAG and PCACG eyes over a period of 3 years, though its efficacy appeared to decrease over time, to a similar extent, in both groups.
本研究旨在比较0.03%比马前列素单药治疗对原发性开角型青光眼（POAG）和原发性慢性闭角型青光眼（PCACG）患者的长期疗效。
在这项为期3年的开放标签、非对照研究中，对55例接受比马前列素单药治疗的成年原发性青光眼患者进行了前瞻性评估。主要结局是评估在3年的随访期内，POAG患者与PCACG患者对治疗反应的差异。
在POAG组中，36个月随访时的平均眼压（IOP）比1个月时的平均眼压升高了2.10（±3.90）mmHg（置信区间[CI]，0.975 - 4.185），P = 0.047。在PCACG组中，36个月随访时的平均眼压比1个月时的平均眼压升高了3.66（±3.34）mmHg（CI，6.241 - 1.092），P = 0.011。与POAG组相比，PCACG组眼压的这种上升趋势更高，但差异无统计学意义（P = 0.54）。在3年随访时，POAG和PCACG患者接受比马前列素单药治疗时眼压<18 mmHg的几率分别为50%和40%（P = 0.23）。
本研究表明，0.03%比马前列素单药治疗在3年内可显著降低POAG和PCACG患者的眼压，尽管两组的疗效似乎都随时间下降，且下降程度相似。
